Terminated PHASE2 INTERVENTIONAL 1-arm NCT00464178

A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma

A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed Refractory Multiple Myeloma

Sponsor: Genentech, Inc.

Interventions Bortezomib

Updated 8 times since 2017 Last updated: Jun 24, 2022 Started: Apr 30, 2007 Primary completion: Feb 28, 2009 Completion: Feb 28, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The study was closed early due to poor accrual

Other terminated trials from Genentech, Inc.

More terminations from Genentech, Inc.

Other Multiple Myeloma trials with similar outcome

Browse all Multiple Myeloma trials

This PHASE2 trial investigates Multiple Myeloma and is currently terminated or withdrawn. Genentech, Inc. leads this study, which shows 8 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Sep 2022 — Jul 2024 [monthly]

Terminated PHASE2

Status: Completed → Terminated
Jan 2021 — Sep 2022 [monthly]

Completed PHASE2
Sep 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Sep 2018 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Apr 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Genentech, Inc.
Hackensack Meridian Health

Data source: Hackensack Meridian Health

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hackensack, United States